CareDx (NASDAQ:CDNA) Price Target Raised to $21.00 at Wells Fargo & Company

CareDx (NASDAQ:CDNA) had its target price increased by Wells Fargo & Company from $18.00 to $21.00 in a report issued on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Several other brokerages also recently commented on CDNA. Zacks Research upgraded CareDx from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Craig Hallum cut shares of CareDx from a “buy” rating to a “hold” rating and set a $26.00 price objective for the company. in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a report on Monday, December 29th. Wall Street Zen cut shares of CareDx from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Finally, BTIG Research lifted their target price on shares of CareDx from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $27.33.

CareDx Price Performance

CareDx stock opened at $18.46 on Wednesday. The firm has a market capitalization of $949.40 million, a PE ratio of -46.15 and a beta of 2.51. The company’s 50-day moving average is $19.66 and its 200-day moving average is $16.75. CareDx has a fifty-two week low of $10.96 and a fifty-two week high of $22.95.

CareDx (NASDAQ:CDNA) last issued its earnings results on Tuesday, February 24th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.12). The firm had revenue of $108.39 million during the quarter, compared to analyst estimates of $102.76 million. CareDx had a negative net margin of 5.65% and a negative return on equity of 6.33%. The company’s revenue for the quarter was up 25.2% on a year-over-year basis. During the same quarter last year, the business posted $0.18 earnings per share. As a group, analysts expect that CareDx will post -0.9 EPS for the current year.

Insider Buying and Selling

In other CareDx news, CEO John Walter Hanna, Jr. sold 19,280 shares of CareDx stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.16, for a total value of $407,964.80. Following the completion of the sale, the chief executive officer owned 597,405 shares in the company, valued at $12,641,089.80. The trade was a 3.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 29,636 shares of company stock worth $625,949 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CareDx

A number of large investors have recently added to or reduced their stakes in the stock. Invesco Ltd. raised its holdings in CareDx by 5.2% in the 4th quarter. Invesco Ltd. now owns 115,503 shares of the company’s stock valued at $2,176,000 after acquiring an additional 5,758 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in CareDx in the 4th quarter valued at about $509,000. Man Group plc raised its position in shares of CareDx by 51.3% in the 4th quarter. Man Group plc now owns 233,171 shares of the company’s stock valued at $4,393,000 after buying an additional 79,009 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of CareDx by 1,213.1% during the 4th quarter. Janus Henderson Group PLC now owns 287,561 shares of the company’s stock worth $5,418,000 after acquiring an additional 265,661 shares during the period. Finally, Gotham Asset Management LLC acquired a new stake in shares of CareDx during the 4th quarter worth approximately $1,556,000.

More CareDx News

Here are the key news stories impacting CareDx this week:

• Positive Sentiment: Revenue beat and strong top‑line growth — CareDx reported Q4 revenue of $108.4M, up ~25% year‑over‑year and above consensus, highlighting continued demand for its transplant diagnostics and services. Press ReleaseView Press Release
• Positive Sentiment: FY‑2026 revenue guidance raised/slightly ahead of Street — management set revenue guidance of $420M–$444M versus a consensus near $417.5M, which provides upside to topline expectations for the year (EPS guidance detail was unclear). Zacks guidance article
• Positive Sentiment: Analyst target lifted — Wells Fargo bumped its price target from $18 to $21 and kept an “equal weight” rating, signaling some analyst confidence in the recovery potential. Benzinga report
• Neutral Sentiment: Internal CFO change — COO Keith Kennedy will also assume CFO responsibilities, a management consolidation that suggests continuity but leaves questions about long‑term finance leadership succession. Business Wire release
• Neutral Sentiment: Short‑interest report appears unreliable — published short‑interest data for late Feb shows zeros/NaN in this dataset and does not indicate a meaningful change in short positioning. Treat the short‑interest signal as inconclusive today.
• Negative Sentiment: EPS miss and investor disappointment — CareDx reported EPS of $0.12 vs. consensus ~$0.24, a material miss that is the primary driver of downward pressure as it raises concerns about near‑term profitability despite revenue strength. Zacks earnings miss

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.